21 Jan 2020 --- Increased competition in the space of nutritional hard capsules has negatively impacted Lonza Group’s fiscal 2019 profits, although the company reports overall strong sales driven by Pharma Biotech & Nutrition (LPBN). Looking to the year ahead, the company intends to appoint a new CEO, commence operations for major investment projects, complete the carve-out of its Specialty Ingredients segment (LSI) and continue to expand production of its undenatured Type II collagen supplement, UC-II. The company is also overseeing new investment, which includes moves in China to support companies developing therapeutic proteins.
